Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy
Functional & Integrative Genomics · 2024-10 · 24 (5)
DOI: 10.1007/s10142-024-01462-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Functional & Integrative Genomics, online erschienen am 04.10.2024. Verfasst von Cigir Biray Avci und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey. Hauptthemen laut MEDLINE: Precision Medicine, Machine Learning, Neoplasms, Pharmacogenetics. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 128 Literaturangaben.
Themen: Künstliche Intelligenz in der Pflege, Onkologische Pflege
Abstract (Originalsprache)
This review analyzes the application of machine learning (ML) in oncological pharmacogenomics, focusing on customizing chemotherapy treatments. It explores how ML can analyze extensive genomic, proteomic, and other omics datasets to identify genetic patterns associated with drug responses. This, in turn, facilitates personalized therapies that are more effective and have fewer side effects. Recent studies have emphasized ML's revolutionary role of ML in personalized oncology treatment by identifying genetic variability and understanding cancer pharmacodynamics. Integrating ML with electronic health records and clinical data shows promise in refining chemotherapy recommendations by considering the complex influencing factors. Although standard chemotherapy depends on population-based doses and treatment regimens, customized techniques use genetic information to tailor treatments for specific patients, potentially enhancing efficacy and reducing adverse effects.However, challenges, such as model interpretability, data quality, transparency, ethical issues related to data privacy, and health disparities, remain. Machine learning has been used to transform oncological pharmacogenomics by enabling personalized chemotherapy treatments. This review highlights ML's potential of ML to enhance treatment effectiveness and minimize side effects through detailed genetic analysis. It also addresses ongoing challenges including improved model interpretability, data quality, and ethical considerations. The review concludes by emphasizing the importance of rigorous clinical trials and interdisciplinary collaboration in the ethical implementation of ML-driven personalized medicine, paving the way for improved outcomes in cancer patients and marking a new frontier in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey.
- Department of Medical Biology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey.
- Stem Cell Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran. noorazarian_a@khoyums.ac.ir.
Zitieren
APA
Avci, C. B., Bagca, B. G., Shademan, B., Takanlou, L. S., Takanlou, M. S., & Nourazarian, A. (2024). Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy. Functional & Integrative Genomics, 24(5). https://doi.org/10.1007/s10142-024-01462-4
Vancouver
Avci CB, Bagca BG, Shademan B, Takanlou LS, Takanlou MS, Nourazarian A. Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy. Functional & Integrative Genomics. 2024;24(5). doi:10.1007/s10142-024-01462-4
BibTeX
@article{Avci2024,
author = {Avci, Cigir Biray and Bagca, Bakiye Goker and Shademan, Behrouz and Takanlou, Leila Sabour and Takanlou, Maryam Sabour and Nourazarian, Alireza},
title = {Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy},
journal = {Functional & Integrative Genomics},
year = {2024},
volume = {24},
number = {5},
doi = {10.1007/s10142-024-01462-4}
}
EUVIMED